Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Follicular 8Sarcoma 3Lymphoma, B-Cell 3Lymphoma 3Prostatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdoid Tumor 1Recurrence 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Inhibition, Psychological 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Chordoma 1

Interventions

Cyclophosphamide 12Etoposide 11Granulocyte Colony-Stimulating Factor 7Filgrastim 7Carboplatin 7etoposide phosphate 6Vincristine 5Methotrexate 5Cisplatin 5fludarabine 4Topotecan 4Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Mesna 4Melphalan 4Temozolomide 3Sirolimus 3Ifosfamide 3Busulfan 3Automobiles 3selinexor 2sargramostim 2fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Leucovorin 2Ipilimumab 2Hydrocortisone 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Rhabdoid Tumor × tazemetostat × Clear all
NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
49 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡